Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascentage Out-Licenses Candidate for Age-Related Eye Disease to Unity Bio

publication date: Jan 9, 2019

Ascentage Pharma of Shanghai out-licensed rights for a small molecule inhibitor of Bcl-2 proteins to treat age-related diseases of the eye to Unity Biotech, a Bay Area company. As an upfront payment, Ascentage will receive shares in Unity Biotech. It will also receive cash milestone payments and royalties based on clinical and commercial milestones. Earlier this week, Ascentage announced a collaboration with MD Anderson Cancer Center to conduct US clinical trials of five cancer drug candidates. More details....

Stock Symbol: (NSDQ: UBX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.